You’re probably already familiar with GLP-1 agonists and their widespread use in weight management. Medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) have now become household names. However, a handful of recent reports have raised a more surprising question: Could these same drugs be helpful for systemic mastocytosis (SM)?
Although it is too early to know for sure, here is what the evidence so far suggests, and what to keep in mind if you’re curious.
What are GLP-1 medications?
Glucagon-like peptide-1 (GLP-1) receptor agonists mimic a natural gut hormone that helps regulate blood sugar and appetite. They were first approved for type 2 diabetes, then for weight management. One of them — tirzepatide (Zepbound) — has also been approved to treat moderate-to-severe obstructive sleep apnea.
What ties these conditions together is that they all involve a persistent, low-grade inflammatory state. A growing body of research suggests that GLP-1 agonists don’t only lower blood sugar and weight — they also appear to regulate inflammation independently of weight loss.
GLP-1 agonists and mast cells
The receptors that GLP-1 medications act on aren’t limited to organs like the pancreas, gut and blood vessels; they’re also expressed on many immune cells, and have been identified on mast cells.
What are mast cells?
Mast cells are specialized cells of the immune system that mediate inflammatory responses and allergic reactions. They are found in the body’s connective tissue.
Some research indicates that mast cells play a role in the low-grade inflammation of fat tissue, which suggests these cells are active participants in the same inflammatory processes GLP-1 drugs appear to dampen.
Mast cells release powerful mediators like histamineHistamine A chemical released by mast cells when they are activated. Histamine causes many of the allergy-type symptoms in mastocytosis, including flushing, itching and hives. that drive inflammation and allergic reactions. Systemic mastocytosisMastocytosis Rare disease caused by the buildup of mast cells. Cutaneous mastocytosis primarily affects the skin and is more common in children, while systemic mastocytosis affects internal organs and is more common in adults. is a mast cellMast cell A type of white blood cell produced in the bone marrow. They help defend against infections and play a key role in allergic reactions. In SM, mast cells become overactive and build up throughout the body. disorder in which mast cells become overactive and release these mediators in excess, causing symptoms across many body systems
In SM, the cells also accumulate abnormally in tissues like the bone marrow, skin and gut. Because they sit at the center of the disease, it makes sense to ask whether a drug that reaches them might help quiet symptoms.
Don’t navigate SM alone. Subscribe to our free weekly newsletter to get the latest stories, perspectives, and information about SM sent directly to your inbox.
What does research on people say?
Although some laboratory studies suggest GLP-1 drugs can act on mast cells, no large controlled trials have been done in mast cell diseaseMast cell disease A group of conditions in which mast cells behave abnormally by building up in excess, releasing chemicals too easily or both. Includes mastocytosis, mast cell activation syndrome and hereditary alpha-tryptasemia. like SM.
However, multiple reports have emerged of patients who started GLP-1 agonists for an approved use, such as diabetes or weight loss, and found along the way that symptoms of their mast cell disorder eased too. A 2025 case series of 47 such patients found that most reported broad relief; however, these patients had mast cell activation syndrome (MCAS), a mast cell disorder distinct from SM.
One report, though, involves SM: In 2023, a woman with long-standing SM began using the GLP-1 drug semaglutide for weight loss and, within two weeks, saw her years-long rashes, flushing, itching and digestive symptoms largely resolve — an improvement that lasted for months.
What researchers don’t yet know
As the research is still scarce, keep in mind that:
- Reports so far involve very few patients, and the improvements were largely self-reported by patients. While intriguing, years of research and testing are needed to know if these drugs carry any benefits for mast cell disease.
- Using these drugs for mast cell symptoms is off-label, meaning they haven’t been approved for this purpose.
- The safest dose, who might benefit and long-term effects are all unknown.
GLP-1 medications are an intriguing area of interest in mast cell disease, but for SM the science is still very early. Remember that any medication changes should be made with a doctor who knows your history — never by starting or stopping medications on your own.
Learn more about systemic mastocytosis treatment and care
